ClinicalTrials.gg
RecruitingNCT07616375Updated Jun 1, 2026

A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis

A Phase 3 interventional study of HSK31858, tablet in Non-cystic Fibrosis Bronchiectasis, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2025, registered May 2026).
  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
669
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 84 studies in Bronchiectasis with a site in China — 35 open to participants now, 38 under way, 4 of them phase 3. Bronchiectasis · China.

Planned enrollment
4th of 50
669 · median 120
Started
2025
with 15 others
Phase 3
7 of 84
4 open now
Primary completion
2029-01
later than 32 of 37 live
Registered
75th of 84
by date
Lead sponsor
7 of 84
Haisco Pharmaceutical Group Co., Ltd.

Among the 84 studies in Bronchiectasis with a site in China, this one is the 4th largest by planned enrollment of the 50 interventional ones that give a count, is one of 16 that started in 2025, is one of 7 in phase 3, reaches primary completion later than 32 of the 37 other live ones, and was the 75th registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

35 of the 84 studies in Bronchiectasis with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Bronchiectasis with a site in China, or all of them as a file.
02

Study summary

This is a phase III, single-arm, open-label, multicenter study to assess the safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.

03

Conditions studied

  • Non-cystic Fibrosis Bronchiectasis

Browse trials for

Keywords

  • non-cystic fibrosis bronchiectasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Voluntarily sign the form; 2.Had previously participated in the HSK31858-301 study (having completed at least the randomization and having taken the first dose of medication); 3.If long-term treatment with bronchodilators (long-acting β-agonists and/or long-acting muscarinic antagonists) is required, the dose and regimen should remain stable throughout the study period.

    4.Women must be , surgically sterile, or using highly effective methods from Day 1 to at least 30 days after the last dose.

    5. Males with female partners of must be using effective contraception from Day 1 to at least 90 days after the last dose.

Exclusion criteria

Exclusion Criteria:

  • 1.In the HSK31858-301 study, there were cases of serious adverse events related to the drug or subjects who were assessed by the investigators as requiring permanent discontinuation of the treatment.

    2. Any other unstable clinical condition, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic, psychiatric, or major physiological dysfunction, that the investigator considers to be (a) likely to affect patient safety throughout the study; (b) Influence the results of the study and its interpretation; (c) impeding the patient\'s ability to complete the entire study.

    3.Pregnancy and lactation. 4.The investigators judged that there were other conditions that were not suitable for participation in the study.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
669 participants (estimated)

Study arms

  • Experimental
    HSK31858 40mg

    HSK31858 40mg treat for 96-week

    Drug: HSK31858, tablet

Interventions

  • HSK31858 is a novel inhibitor of DPP1 developed by Hisco Pharmaceutical and can reduce pulmonary exacerbations over a 52-week treatment period in patients with non-cystic fibrosis bronchiectasis

06

What researchers measure

Primary outcomes

  1. AE

    Occurrence of adverse events

    Time frame: week 96

Secondary outcomes

  1. Frequency of pulmonary exacerbations

    Time frame: week 96

  2. Change from Baseline(Screening) in forced expiratory volume in 1 second (FEV1)

    Time frame: week 96

  3. Change from Baseline in the Respiratory Symptoms Domain Score of the Quality of Life (QOL) Bronchiectasis questionnaire

    score from 0 to 100

    Time frame: week 96

  4. Change from Baseline(Screening) in 24-hour Sputum Weight and Sputum purulence score

    score from 0 to 8

    Time frame: week 96

07

Study locations

1 of 1 sites recruiting
  • Yixing People's Hospital, Yixing, Jiangxi Recruiting
    Yixingcun, Jiangxi, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jan 2029, 39 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2026
First posted
Jun 1, 2026
StartActual
Sep 28, 2025
Primary completionEst.
Jan 10, 2029
CompletionEst.
Apr 3, 2029
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07616375
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Sep 28, 2025
Primary completion
Jan 10, 2029 (estimated)
Completion
Apr 3, 2029 (estimated)
Last update
Jun 1, 2026

Study contacts

Guan Wei Jie
Contact
battery203@163.com
86-13826042052

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Florensocatib

Start the discussion